Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | PADI1 | Q9ULC6 | 1/20 | 0.38 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL840429 | 1.00 | MEN1 (0.40) | MEN1KMT2APADI1PADI4MAPT | |
| SCHEMBL31758131 | 0.96 | MEN1 (0.45) | MEN1KMT2APADI1PADI4MAPT | |
| SCHEMBL26421960 | 0.90 | ALDH1A1 (0.38) | MEN1KMT2APADI1PADI4MAPT | |
| SCHEMBL31757749 | 0.83 | USP2 (0.52) | CYP2D6ALDH1A1L3MBTL1HSD17B10KDM4E | |
| SCHEMBL22354590 | 0.81 | ALDH1A1 (0.41) | MEN1KMT2AMAPTATMCYP2D6 | |
| SCHEMBL23886458 | 0.80 | CHRM2 (0.42) | PADI1PADI4CYP2D6ALDH1A1POLB | |
| SCHEMBL24673361 | 0.79 | CYP2D6 (0.32) | PADI1PADI4MAPTCYP2D6ALDH1A1 | |
| SCHEMBL2959602 | 0.78 | KMT2A (0.43) | MEN1KMT2AMAPTATMALDH1A1 | |
| SCHEMBL64561 | 0.76 | CHRM2 (0.46) | MEN1KMT2APADI1PADI4MAPT | |
| SCHEMBL5828933 | 0.76 | MEN1 (0.41) | MEN1KMT2AMAPTATMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143263-B2 | Therapeutic agents | ASTRAZENECA AB (SE) | 2012-03-27 | — | — | US | disclosed |
| US-20100093757-A1 | THERAPEUTIC AGENTS 414 | ASTRAZENECA AB (SE) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093757-A1 | THERAPEUTIC AGENTS 414 | GCK, GCKR, GPR119 | MEN1 2410/4885KMT2A 4136/4885PADI1 4220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.